Rhythm Pharmaceuticals
RYTM
98 hedge funds and large institutions have $483M invested in Rhythm Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 12 closing their positions.
71% more call options, than puts
Call options by funds: $154K | Put options by funds: $90K
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
1% more funds holding
Funds holding: 97 → 98 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0.91% more ownership
Funds ownership: 95.47% → 96.39% (+0.91%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less capital invested
Capital invested by funds: $626M → $483M (-$142M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$15.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.2M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$2.22M |
| 4 |
Goldman Sachs
New York
|
+$2.15M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$19.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.3M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.33M |
| 4 |
DM
Deerfield Management
New York
|
-$1.37M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.12M |
RYTM Hedge Fund Activity: Q4 2021 in Review
98 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2021, worth a combined $483M — down 23% from $626M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RYTM positions and 12 closed out — a net gain of 1 holder — while 39 added to existing stakes and 29 trimmed.
The largest buyer was Franklin Resources, adding an estimated $15.4M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $19.5M sold.
- 98 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2021, up from 97 in Q3 2021.
- Funds reported $483M of Rhythm Pharmaceuticals stock for Q4 2021, down 23% quarter-over-quarter.
- 13 funds opened new Rhythm Pharmaceuticals positions in Q4 2021 and 12 closed out, a net change of +1 holder.
- The largest Rhythm Pharmaceuticals buyer in Q4 2021 was Franklin Resources, an estimated $15.4M added.
- The largest Rhythm Pharmaceuticals seller in Q4 2021 was Gilder Gagnon Howe & Co, an estimated $19.5M sold.
Based on aggregated 13F filings for Q4 2021.